Luigia Elzi
Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen.
Marzolini C, Cavassini M, Braun D, Hachfeld A, Bernasconi E, Calmy A, Schmid P, Battegay M, Elzi L, Swiss HIV Cohort Study S. Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen. Br J Clin Pharmacol 2023
26.04.2023Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor containing regimen.
26.04.2023Br J Clin Pharmacol 2023
Marzolini Catia, Cavassini Matthias, Braun Dominique Laurent, Hachfeld Anna, Bernasconi Enos, Calmy Alexandra, Schmid Patrick, Battegay Manuel, Elzi Luigia, Swiss HIV Cohort Study SHCS
Adverse events of raltegravir and dolutegravir
Elzi L, Battegay M, Bernasconi E, Günthard H, Vernazza P, Calmy A, Cavassini M, Furrer H, Erb S. Adverse events of raltegravir and dolutegravir. AIDS 2017; 31:1853-1858.
24.08.2017Adverse events of raltegravir and dolutegravir
24.08.2017AIDS 2017; 31:1853-1858
Elzi Luigia, Battegay Manuel, Bernasconi Enos, Günthard Huldrych, Vernazza Pietro, Calmy Alexandra, Cavassini Matthias, Furrer Hansjakob, Erb Stefan
Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study
Elzi L, Furrer H, Bernasconi E, Schmid P, Calmy A, Cavassini M, Fehr J, Patzen A, Conen A, Battegay M. Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. Open Forum Infect Dis 2016; 3:ofw022.
01.02.2016Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study
01.02.2016Open Forum Infect Dis 2016; 3:ofw022
Elzi Luigia, Furrer Hansjakob, Bernasconi Enos, Schmid Patrick, Calmy Alexandra, Cavassini Matthias, Fehr Jan, Patzen Annalea, Conen Anna, Battegay Manuel
Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis?
Babouee Flury B, Elzi L, Kolbe M, Frei R, Maja W, Schären S, Widmer A, Battegay M. Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis?. BMC Infect Dis 2014; 14:226.
27.04.2014Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis?
27.04.2014BMC Infect Dis 2014; 14:226
Babouee Flury Baharak, Elzi Luigia, Kolbe Marko, Frei Reno, Maja Weisser, Schären Stefan, Widmer Andreas F, Battegay Manuel
Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, the Swiss HIV Cohort Study (SHCS). Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. PloS one 2013; 8
25.07.2013Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
25.07.2013PloS one 2013; 8
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Aubert Vincent, Klimkait Thomas, Yerly Sabine, Böni Jürg, the Swiss HIV Cohort Study (SHCS)
Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS)
Nüesch R, Bucher H, Battegay M, Calmy A, Thurnheer M, Vernazza P, Cavassini M, Weber R, Bernasconi E, Elzi L, Wang Q, Swiss HIV Cohort Study. Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). J Acquir Immune Defic Syndr 2013; 62:396-404.
01.04.2013Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS)
01.04.2013J Acquir Immune Defic Syndr 2013; 62:396-404
Nüesch Reto, Bucher Heiner C, Battegay Manuel, Calmy Alexandra, Thurnheer Maria C, Vernazza Pietro, Cavassini Matthias, Weber Rainer, Bernasconi Enos, Elzi Luigia, Wang Qing, Swiss HIV Cohort Study
Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study
Boillat-Blanco N, Wandeler G, Fehr J, Daou S, Elzi L, Adami M, Strahm C, Osih R, Taffé P, Darling K, Cavassini M. Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study. J Acquir Immune Defic Syndr 2013; 62:180-9.
01.02.2013Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study
01.02.2013J Acquir Immune Defic Syndr 2013; 62:180-9
Boillat-Blanco Noémie, Wandeler Gilles, Fehr Jan, Daou Samira, Elzi Luigia, Adami Maddalena, Strahm Carol, Osih Regina, Taffé Patrick, Darling Katharine E A, Cavassini Matthias
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, Swiss HIV Cohort Study (SHCS). Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. PloS one 2012; 7:e50307.
26.11.2012Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
26.11.2012PloS one 2012; 7:e50307
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Aubert Vincent, Klimkait Thomas, Yerly Sabine, Böni Jürg, Swiss HIV Cohort Study (SHCS)
Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes
Elzi L, Battegay M, Weber R, Bernasconi E, Vernazza P, Hirschel B, Cavassini M, Ledergerber B, Furrer H, Erb S, for the Swiss HIV Cohort Study. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. Arch Intern Med 2012:1-9.
13.08.2012Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes
13.08.2012Arch Intern Med 2012:1-9
Elzi Luigia, Battegay Manuel, Weber Rainer, Bernasconi Enos, Vernazza Pietro, Hirschel Bernard, Cavassini Matthias, Ledergerber Bruno, Furrer Hansjakob, Erb Stefan, for the Swiss HIV Cohort Study
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
Scherrer A, Günthard H, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Cellerai C, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PloS one 2012; 7:e37983.
18.06.2012Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
18.06.2012PloS one 2012; 7:e37983
Scherrer Alexandra U, Günthard Huldrych F, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Cellerai Cristina, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Ledergerber Bruno, Swiss HIV Cohort Study
Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study
Staehelin C, Furrer H, Bernasconi E, Schmid P, Cavassini M, Elzi L, Weber R, Calmy A, Keiser O, Swiss HIV Cohort Study. Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2012; 59:79-85.
01.01.2012Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study
01.01.2012J Acquir Immune Defic Syndr 2012; 59:79-85
Staehelin Cornelia, Furrer Hansjakob, Bernasconi Enos, Schmid Patrick, Cavassini Matthias, Elzi Luigia, Weber Rainer, Calmy Alexandra, Keiser Olivia, Swiss HIV Cohort Study
Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic
Boillat Blanco N, Cavassini M, Bertisch B, Weber R, Rauch A, Elzi L, Calmy A, Bernasconi E, Giulieri S, Da Costa V, Probst A, Bochud P. Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic. J Acquir Immune Defic Syndr 2011; 58:472-4.
15.12.2011Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic
15.12.2011J Acquir Immune Defic Syndr 2011; 58:472-4
Boillat Blanco Noémie, Cavassini Matthias, Bertisch Barbara, Weber Rainer, Rauch Andri, Elzi Luigia, Calmy Alexandra, Bernasconi Enos, Giulieri Stefano, Da Costa Vreneli Waelti, Probst Arnold, Bochud Pierre-Yves
Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection
Elzi L, Bassetti S, Bernasconi E, Hoffmann M, Hirschel B, Cavassini M, Fehr J, Furrer H, Steffen I, Battegay M. Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection. BMC Infect Dis 2011; 11:319.
15.11.2011Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection
15.11.2011BMC Infect Dis 2011; 11:319
Elzi Luigia, Bassetti Stefano, Bernasconi Enos, Hoffmann Matthias, Hirschel Bernard, Cavassini Matthias, Fehr Jan, Furrer Hansjakob, Steffen Ingrid, Battegay Manuel
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B
Scherrer A, Günthard H, Held L, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Hirschel B, Rauch A, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis 2011; 53:1143-52.
13.10.2011Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B
13.10.2011Clin Infect Dis 2011; 53:1143-52
Scherrer Alexandra U, Günthard Huldrych F, Held Leonhard, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Hirschel Bernard, Rauch Andri, Bürgisser Philippe, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Ledergerber Bruno, Swiss HIV Cohort Study
A comment on Marschall et Al
Babouee Flury B, Elzi L, Frei R, Widmer A, Battegay M. A comment on Marschall et Al. Clin Infect Dis 2011; 53:748, author reply 748-9.
01.10.2011A comment on Marschall et Al
01.10.2011Clin Infect Dis 2011; 53:748, author reply 748-9
Babouee Flury Baharak, Elzi Luigia, Frei Reno, Widmer Andreas, Battegay Manuel
A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)
Nguyen A, Schmid P, Bernasconi E, Rauch A, Elzi L, Mello A, Cavassini M, Mercier I, Delhumeau C, Calmy A, Hirschel B. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011; 25:1481-7.
31.07.2011A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)
31.07.2011AIDS 2011; 25:1481-7
Nguyen Alain, Schmid Patrick, Bernasconi Enos, Rauch Andri, Elzi Luigia, Mello Aurelie F, Cavassini Matthias, Mercier Isabelle, Delhumeau Cécile, Calmy Alexandra, Hirschel Bernard
Ageing with HIV: medication use and risk for potential drug-drug interactions
Marzolini C, Elzi L, Battegay M, Khoo S, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Furrer H, Weber R, Back D, Swiss HIV Cohort Study Members. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66:2107-11.
16.06.2011Ageing with HIV: medication use and risk for potential drug-drug interactions
16.06.2011J Antimicrob Chemother 2011; 66:2107-11
Marzolini Catia, Elzi Luigia, Battegay Manuel, Khoo Saye, Bernasconi Enos, Vernazza Pietro, Calmy Alexandra, Cavassini Matthias, Furrer Hansjakob, Weber Rainer, Back David, Swiss HIV Cohort Study Members
Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland
Kenfak-Foguena A, Cavassini M, Izpopet J, Abravanel F, Moradpour D, Jost J, Gurter-De La Fuente V, Elzi L, Evison J, Kaiser L, Kovari H, Darling K, Witteck A, Bürgisser P, Schöni-Affolter F, Data Center of the Swiss HIV Cohort Study, Lausanne, Switzerland. Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland. Emerging Infect Dis 2011; 17:1074-8.
01.06.2011Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland
01.06.2011Emerging Infect Dis 2011; 17:1074-8
Kenfak-Foguena Alain, Cavassini Matthais, Izpopet Jacques, Abravanel Florence, Moradpour Darius, Jost Josef, Gurter-De La Fuente Vanina, Elzi Luigia, Evison John-Marc, Kaiser Laurent, Kovari Helen, Darling Katharine E A, Witteck Andrea, Bürgisser Phillippe, Schöni-Affolter Franziska, Data Center of the Swiss HIV Cohort Study, Lausanne, Switzerland
Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death
Kaufmann G, Battegay M, Hirschel B, Bernasconi E, Vernazza P, Giulieri S, Furrer H, Weber R, Elzi L, Swiss HIV Cohort Study. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS 2011; 25:441-51.
20.02.2011Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death
20.02.2011AIDS 2011; 25:441-51
Kaufmann Gilbert R, Battegay Manuel, Hirschel Bernard, Bernasconi Enos, Vernazza Pietro, Giulieri Stefano, Furrer Hansjakob, Weber Rainer, Elzi Luigia, Swiss HIV Cohort Study
No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy
Ortiz M, Tarr P, Telenti A, Günthard H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Elzi L, Arnedo M, Martinez R, Kovari H, Furrer H, Poloni E, Swiss HIV Cohort Study. No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. J Infect Dis 2011; 203:620-4.
12.01.2011No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy
12.01.2011J Infect Dis 2011; 203:620-4
Ortiz Millán, Tarr Philip E, Telenti Amalio, Günthard Huldrych F, Ledergerber Bruno, Cavassini Matthias, Hirschel Bernard, Vernazza Pietro, Bernasconi Enos, Elzi Luigia, Arnedo Mireia, Martinez Raquel, Kovari Helen, Furrer Hansjakob, Poloni Estella S, Swiss HIV Cohort Study